Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fulcrum Therapeutics, Inc. FULC
$3.23
+$0.05 (1.42%)
На 18:01, 12 мая 2023
+348.92%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
197937595.00000000
-
week52high
15.00
-
week52low
2.25
-
Revenue
6342000
-
P/E TTM
-1
-
Beta
2.11826900
-
EPS
-2.69000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 13 июн 2022 г. |
| Morgan Stanley | Overweight | Overweight | 17 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 12 апр 2022 г. |
| Credit Suisse | Outperform | Outperform | 25 мар 2022 г. |
| Oppenheimer | Outperform | 08 мар 2022 г. | |
| Goldman Sachs | Buy | 15 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 14 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 09 ноя 2022 г. |
| Goldman Sachs | Buy | Buy | 19 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
| Piper Sandler | Overweight | Overweight | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | A | 11609704 | 1923076 | 20 янв 2023 г. |
| Gould Robert J | D | 499864 | 6766 | 13 янв 2023 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 9686628 | 58369 | 04 янв 2023 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 9628259 | 122334 | 04 янв 2023 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 9505925 | 4089 | 27 дек 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 9501836 | 98787 | 19 дек 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 9403049 | 1341420 | 16 дек 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 8061629 | 237029 | 15 дек 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 7824600 | 824600 | 14 дек 2022 г. |
| Third Rock Ventures III, L.P. | D | 1962202 | 2000000 | 13 дек 2022 г. |
Новостная лента
5 Best and Worst Performing Small-Cap Stocks in February 2023
24/7 Wall Street
13 мар 2023 г. в 22:51
Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 09:53
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
GlobeNewsWire
06 мар 2023 г. в 16:05
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2022 financial results will be released on Thursday, March 9, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News
InvestorPlace
24 февр 2023 г. в 11:09
There's no doubt Fulcrum Therapeutics (NASDAQ: FULC ) is committed to advancing its proposed treatment for sickle cell disease. However, there's a regulatory holdup.
Are You Looking for a Top Momentum Pick? Why Fulcrum Therapeutics, Inc. (FULC) is a Great Choice
Zacks Investment Research
01 февр 2023 г. в 13:32
Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.